Page last updated: 2024-11-08

cgs 20625

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

CGS 20625: benzodiazepine receptor agonists; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID163844
CHEMBL ID1395823
CHEBI ID93192
SCHEMBL ID9691852
SCHEMBL ID17236323
MeSH IDM0154396

Synonyms (30)

Synonym
HMS3269G13
NCGC00159576-01
cgs 20625
2-(4-methoxyphenyl)-1,6,7,8,9,10-hexahydrocyclohepta[b]pyrazolo[3,4-d]pyridin-3(2h)-one
111205-55-1
cgs-20625
k9q4r9s81o ,
cyclohepta(b)pyrazolo(3,4-d)pyridin-3(2h)-one, 5,6,7,8,9,10-hexahydro-2-(4-methoxyphenyl)-
unii-k9q4r9s81o
5,6,7,8,9,10-hexahydro-2-(4-methoxyphenyl)cyclohepta[b]pyrazolo[3,4-d]pyridin-3(2h)-one
bdbm84993
BRD-K68103045-001-01-1
SCHEMBL9691852
CHEMBL1395823
AKOS024457117
SCHEMBL17236323
J-002543
CHEBI:93192
DTXSID30912046
lsm-3520
Q5010987
HMS3677O20
HMS3413O20
BCP33079
cgs20625;cgs-20625
5,6,7,8,9,10-hexahydro-2-(4-methoxyphenyl)cyclohepta[b]pyrazolo[3,4-d]pyridin-3(2h)-one.
4-(4-methoxyphenyl)-3,4,8-triazatricyclo[7.5.0.02,6]tetradeca-1,6,8-trien-5-one
HY-106316
CS-0025570
PD032935

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
"Oral bioavailability of highly water-insoluble drugs is often quite limited and variable, requiring the development of improved formulations."( Oral absorption of CGS-20625, an insoluble drug, in dogs and man.
Hirschberg, Y; Lau, H; Markowska, M; Oberle, RL; Ortiz, M, 1995
)
0.29

Dosage Studied

ExcerptRelevanceReference
" Comparison of the dose-response curves demonstrated a difference in the intensity of the stimulus effects."( The discriminative stimulus effects of diazepam in rats at two training doses.
Franklin, SR; Tang, AH, 1991
)
0.28
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (2)

ClassDescription
pyrazoles
ring assemblyTwo or more cyclic systems (single rings or fused systems) which are directly joined to each other by double or single bonds are named ring assemblies when the number of such direct ring junctions is one less than the number of cyclic systems involved.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (3)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Microtubule-associated protein tauHomo sapiens (human)Potency12.67280.180013.557439.8107AID1460; AID1468
glucocerebrosidaseHomo sapiens (human)Potency28.18380.01268.156944.6684AID2101
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency17.78280.035520.977089.1251AID504332
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (2)

Assay IDTitleYearJournalArticle
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (9)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (22.22)18.7374
1990's4 (44.44)18.2507
2000's1 (11.11)29.6817
2010's0 (0.00)24.3611
2020's2 (22.22)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.53

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.53 (24.57)
Research Supply Index2.30 (2.92)
Research Growth Index4.83 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.53)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (11.11%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other8 (88.89%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]